BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Amano S, Kaino S, Shinoda S, Harima H, Matsumoto T, Fujisawa K, Takami T, Yamamoto N, Yamasaki T, Sakaida I. Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox. BMC Cancer 2020;20:681. [PMID: 32698792 DOI: 10.1186/s12885-020-07167-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Harismah K, Hajali N, Zandi H. 6-Thioguanine bimolecular formation for dual chelation of iron: DFT study. Computational and Theoretical Chemistry 2021;1202:113308. [DOI: 10.1016/j.comptc.2021.113308] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Zhou N, Cui Y, Zhu R, Kuang Y, Ma W, Hou J, Zhu Y, Chen S, Xu X, Tan K, Cao P, Duan X, Fan Y. Deferasirox shows inhibition activity against cervical cancer in vitro and in vivo. Gynecologic Oncology 2022. [DOI: 10.1016/j.ygyno.2022.05.006] [Reference Citation Analysis]
3 Torti SV, Torti FM. Iron and Cancer: 2020 Vision. Cancer Res 2020;80:5435-48. [PMID: 32928919 DOI: 10.1158/0008-5472.CAN-20-2017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
4 Noulsri E, Lerdwana S. Attenuation of tryptophan metabolism by Fe chelators: A hypothesis regarding inhibiting tumor suppressive microenvironments in pancreatic ductal adenocarcinoma. Medical Hypotheses 2022;165:110907. [DOI: 10.1016/j.mehy.2022.110907] [Reference Citation Analysis]
5 Moghadam SMM, Alibolandi M, Babaei M, Mosafer J, Saljooghi AS, Ramezani M. Fabrication of deferasirox-decorated aptamer-targeted superparamagnetic iron oxide nanoparticles (SPION) as a therapeutic and magnetic resonance imaging agent in cancer therapy. J Biol Inorg Chem 2021;26:29-41. [PMID: 33156416 DOI: 10.1007/s00775-020-01834-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
6 Shen L, Zhou Y, He H, Chen W, Lenahan C, Li X, Deng Y, Shao A, Huang J. Crosstalk between Macrophages, T Cells, and Iron Metabolism in Tumor Microenvironment. Oxid Med Cell Longev 2021;2021:8865791. [PMID: 33628389 DOI: 10.1155/2021/8865791] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
7 Abedi M, Rahgozar S. Puzzling Out Iron Complications in Cancer Drug Resistance. Crit Rev Oncol Hematol 2022;:103772. [PMID: 35914667 DOI: 10.1016/j.critrevonc.2022.103772] [Reference Citation Analysis]
8 Szymonik J, Wala K, Górnicki T, Saczko J, Pencakowski B, Kulbacka J. The Impact of Iron Chelators on the Biology of Cancer Stem Cells. Int J Mol Sci 2021;23:89. [PMID: 35008527 DOI: 10.3390/ijms23010089] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Argenziano M, Tortora C, Paola AD, Pota E, Martino MD, Pinto DD, Leva CD, Rossi F. Eltrombopag and its iron chelating properties in pediatric acute myeloid leukemia. Oncotarget 2021;12:1377-87. [PMID: 34262648 DOI: 10.18632/oncotarget.28000] [Reference Citation Analysis]
10 Ali A, Shafarin J, Unnikannan H, Al-Jabi N, Jabal RA, Bajbouj K, Muhammad JS, Hamad M. Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer. Int J Biol Sci 2021;17:4474-92. [PMID: 34803511 DOI: 10.7150/ijbs.62236] [Reference Citation Analysis]
11 Ni S, Yuan Y, Kuang Y, Li X. Iron Metabolism and Immune Regulation. Front Immunol 2022;13:816282. [PMID: 35401569 DOI: 10.3389/fimmu.2022.816282] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Guan LY, Lv JQ, Zhang DQ, Li B. Collective Polarization of Cancer Cells at the Monolayer Boundary. Micromachines (Basel) 2021;12:112. [PMID: 33499191 DOI: 10.3390/mi12020112] [Reference Citation Analysis]
13 Liu K, Huang J, Liu J, Li C, Kroemer G, Tang D, Kang R. HSP90 Mediates IFNγ-Induced Adaptive Resistance to Anti-PD-1 Immunotherapy. Cancer Res 2022;82:2003-18. [PMID: 35247909 DOI: 10.1158/0008-5472.CAN-21-3917] [Reference Citation Analysis]
14 Poonkuzhi Naseef P, Elayadeth-Meethal M, Salim K T M, Anjana A, Muhas C, Vajid K A, Saheer Kuruniyan M. Therapeutic Potential Of Induced Iron Depletion Using Iron Chelators In Covid-19. Saudi J Biol Sci 2021. [PMID: 34924800 DOI: 10.1016/j.sjbs.2021.11.061] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]